Anti-Alzheimer’s multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity.

The research article talks about the exploration and development of multi-functional drugs that act as serotonin 5-HT6 antagonists, butyrylcholinesterase inhibitors, and antioxidants to combat Alzheimer’s disease.

Understanding Alzheimer’s Pathophysiology

• The research begins by discussing the underlying physiological causes of Alzheimer’s disease which revolve around three primary elements: serotonin 5-HT6 receptors, butyrylcholinesterase (BuChE) and oxidative stress.
• Serotonin 5-HT6 receptors are involved in learning and memory, and their overstimulation can lead to cognitive impairment, hence the idea of developing drugs that can antagonize these receptors.
• Butyrylcholinesterase is an enzyme known to break down acetylcholine, a neurotransmitter vital for learning and memory. In Alzheimer’s disease, there is an increased activity of BuChE leading to lower levels of acetylcholine, hence the need for drugs that can inhibit the activity of BuChE.
• Oxidative stress resulting from the imbalance between the production of reactive oxygen species and the body’s ability to detoxify them or repair the resulting damage is another key factor influencing Alzheimer’s disease. Thus, the need for drugs that can also act as antioxidants.

Development of Multitarget-Directed Ligands

• The researchers propose the idea of creating multi-target directed ligands combining the properties of serotonin 5-HT6 receptor antagonism, butyrylcholinesterase inhibition, and antioxidant activity. Such a drug could not only improve cognitive abilities but also reduce neurodegeneration, providing a more comprehensive approach in Alzheimer’s disease treatment.
• After an initial screening of compounds that antagonize the 5-HT6 receptors for their BuChE inhibitory activity, the authors selected two compounds for further development. These compounds were then structurally modified to improve their BuChE inhibitory activity.
• The researchers synthesized two series of compounds and tested their functionality against 5-HT6 receptors, their BuChE inhibitory activity, and their antioxidant properties.

Promising Results

• Of the tested compounds, Compound 12 stood out due to its promising properties.
• Compound 12 was able to antagonize the 5-HT6 receptors sufficiently, inhibit BuChE activity, and portrayed antioxidant properties even surpassing those of ascorbic acid, a well-known antioxidant.
• The researchers concluded that Compound 12 could potentially be a vital structure for the further development of multi-functional anti-Alzheimer’s agents encompassing all the three crucial elements involved in the disease’s pathophysiology.